Sugi Predict

Sugi Predict / Compounds / SCHEMBL2201610

SCHEMBL2201610

SCHEMBL2201610

Cc1ccc(O[Si](C)(C)C(C)(C)C)cc1-c1cc(-c2ccncc2)nc2[nH]nc(N)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 5/20 0.38
▸ CDC7 O00311 4/20 0.38
▸ MAP4K4 O95819 4/20 0.38
▸ PIM1 P11309 4/20 0.38
▸ PRKACA P17612 4/20 0.38
▸ CDK2 P24941 4/20 0.38
▸ GSK3B P49841 4/20 0.38
▸ HIPK2 Q9H2X6 4/20 0.38
▸ CLK4 Q9HAZ1 4/20 0.38
▸ IRAK4 Q9NWZ3 4/20 0.38
▸ CDK7 P50613 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ MKNK2 Q9HBH9 1/20 0.33
▸ SGK1 O00141 2/20 0.33
▸ BTK Q06187 3/20 0.32
▸ ACHE P22303 3/20 0.32
▸ CA12 O43570 4/20 0.32
▸ CA1 P00915 4/20 0.32
▸ CA9 Q16790 4/20 0.32
▸ PDPK1 O15530 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202020 0.84 CA12 (0.34) BTKCA12CA1CA9
SCHEMBL2198974 0.79 GSK3B (0.38) ROCK2CDC7MAP4K4PIM1PRKACA
SCHEMBL2201274 0.72 ACHE (0.45) ROCK2CDC7MAP4K4PIM1PRKACA
SCHEMBL6115704 0.70 BTK (0.56) BTKACHE
SCHEMBL2200671 0.70 ACHE (0.41) ROCK2CDC7MAP4K4PIM1PRKACA
SCHEMBL13329663 0.70 ACHE (0.52) CDC7GSK3BMKNK2BTKACHE
SCHEMBL2198887 0.67 SQOR (0.41) CA12CA1CA9
SCHEMBL2202555 0.66 PIK3CA (0.41) ROCK2CDC7MAP4K4PIM1PRKACA
SCHEMBL2201617 0.65 BIRC5 (0.43) PIM1
SCHEMBL2849242 0.64 HSP90AA1 (0.52) CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846402-B1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES BAYER IP GMBH (DE) 2014-02-26 — — EP disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 — — US disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 — — US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 — — US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents MAP4K2, ABL1, MAP4K3 ROCK2 368/4885CDC7 960/4885MAP4K4 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.